Should you buy Sanofi (SNY) stock in 2026?

2026-08-03 · By Lubin Danilo, founder of Lubin Investment

SNY: see the full analysis on Lubin Investment

Sanofi validates only 5 of my 10 quality criteria: decent profitability, but sales growth and free cash flow per share that are too weak, even declining. The price looks reasonable (16.5 times free cash flow), yet my model flags a severe 53% overvaluation. Here is how middling quality and a seemingly sensible price can still add up to a bad bet.

The name everyone knows, the question almost nobody asks

Sanofi is one of those companies everyone has heard of without necessarily knowing it trades on the stock market: one of France's largest pharmaceutical employers, a name that keeps coming up in health news. That kind of familiarity often leads to a dangerous shortcut: a company that established must surely be a safe investment. That is exactly the confusion I refuse to make. Size and name recognition say nothing about the financial quality of the business, or about the price it trades at today.

The immediate trigger here is the good surprise from July 30: Sanofi posted earnings per share of $2.09 for the second quarter of 2026, well above the $1.92 analysts expected (+8.9%), and revenue of $13.48 billion, also above consensus. A strong quarterly print. But my approach never judges a stock on a single quarter: it looks at the five-year trend, far harder to dress up than one isolated number. And over five years, Sanofi's story is more nuanced than this quarter suggests.

A profitable company that barely grows

Sanofi validates only 5 of my 10 financial criteria. It is profitable (17.2% net margin) and keeps its share count under control (a slight 0.49% annual decline, a sign of net buybacks rather than dilution). But two signals are far more worrying: five-year sales growth tops out at 2.7% a year, well below my 10% threshold, and free cash flow per share has fallen 6.2% a year over the same period. That is not a slowdown, it is a real decline: each Sanofi share generates less cash today than it did five years ago. A third negative signal: my criteria detect margin compression, with costs growing faster than revenue.

This decline in cash per share can be surprising given that Dupixent, Sanofi's flagship treatment for severe eczema, asthma and other inflammatory diseases, jumped 31% in the first quarter of 2026 to €4.2 billion in sales, and management even raised its full-year growth guidance to about 10% at constant exchange rates. The mechanic behind this apparent paradox is a classic in pharma: what is known as the patent cliff. Sanofi's older blockbuster drugs progressively lose patent protection and face competition from far cheaper generics, eroding their sales year after year. For now, a single product, Dupixent, carries most of the group's growth, while Sanofi reinvests heavily in research to defend that success (a new quarterly-dosing formulation entering clinical trials in the second half of 2026, an extension into high-dose asthma) and to build what comes after Dupixent with a diversified pipeline: two promising molecules, lunsekimig for asthma and amlitelimab for atopic dermatitis, just delivered positive phase II results. This ongoing research effort weighs on margins and on cash available today, in exchange for a bet on tomorrow's growth.

What I cannot calculate, and why I say so

Two of my criteria remain uncalculable for Sanofi, for lack of sufficient data from my financial data provider: cash return on capital employed (total assets are unavailable) and the net cash conversion cycle. I would rather say so plainly than invent a number: my 5/10 score excludes these two criteria rather than counting them as automatic failures. One last signal deserves attention: only 43% of Sanofi's accounting profit turns into cash actually available, below my 100% threshold. Part of the reported profit therefore stays on paper, a common phenomenon at large pharmaceutical groups where capitalized R&D, legal provisions and amortization create a gap between accounting profit and real cash.

The price: cheap versus peers, expensive versus its own mirror

Sanofi currently trades at 16.5 times its free cash flow (P/FCF). Compared with its global pharma peers (AbbVie at 21.1 times, Merck at 22.4 times, AstraZeneca at 33.5 times, Eli Lilly at 53.7 times), that level places it at the sector's 34th percentile: cheaper than the median of its competitors. On this metric alone, the stock looks like a bargain.

But it also needs to be compared with itself. Set against its own five-year history, that same 16.5-times P/FCF sits at the 79th percentile: Sanofi has rarely paid this much for its own cash. In other words, the stock is cheap relative to a sector that trades cautiously overall, but expensive relative to its own historical standards, where it often traded cheaper still.

Third step, the verdict, and this is where my model diverges most from the raw multiple: I do not just look at the current P/FCF, I project the five-year cash-per-share trajectory. That trajectory is currently negative (-6.2% a year). A 16.5-times P/FCF applied to a shrinking cash-per-share figure is worth much less than the same multiple applied to a growing one. That is why my model puts the fair buy price at just $20.21, against a current price of $42.95, a 52.9% overvaluation.

The real debate: can Dupixent carry the whole group alone?

The whole Sanofi thesis rests on this tension. On one side, Dupixent's momentum is real and well documented (+31% in the first quarter, raised full-year guidance), and the first results from the diversification pipeline (lunsekimig, amlitelimab) suggest the defend-and-extend strategy is progressing. If these new growth drivers take over before older drugs erode further and before Dupixent's own patent expires in 2031, the current decline in cash per share could reverse. On the other side, my method relies on the realized five-year trend, not pipeline promises: and that trend shows sales growth that is too weak and cash per share that is falling, while a single product carries most of the momentum. The market does not seem to have fully priced in this concentration risk, which explains the gap between the seemingly sensible multiple and my model's harsh verdict.

How I settle it

Sanofi is not a bad company: it remains profitable, with a genuine commercial success in Dupixent and a diversification pipeline showing encouraging signals. But my quality screen (5/10) and my price model both point the same unusual way for a supposedly stable big pharma name: middling quality, a price that is no less demanding despite misleading appearances. I am not betting against Sanofi, I am marking a price and waiting for it to come to me. You can follow these numbers live on Sanofi's analysis page, and understand in detail how I calculate this fair buy price in my full methodology.

Sanofi validates only 5 of my 10 criteria: profitable (17.2% net margin) but sales growth (2.7%/year) and free cash flow per share (-6.2%/year, declining) both fall short, with margins compressing.
The decline in cash per share reflects the classic pharma patent cliff: older drugs erode against generics while a single product (Dupixent, +31% in Q1 2026) carries most of the growth and diversification R&D weighs on margins.
P/FCF of 16.5 times: cheap versus sector peers (34th percentile, median 21.4 times) but expensive versus its own history (79th percentile).
My model flags a severe 52.9% overvaluation (fair buy price of $20.21 against a $42.95 price), because it projects a declining, not growing, cash-per-share trajectory.
Strong second-quarter 2026 results (EPS of $2.09 beating consensus by 8.9%, revenue of $13.48B): solid short-term execution that does not yet reverse the underlying five-year trend.

FAQ

Is Sanofi a quality stock by your method?

Only 5 of 10 criteria pass: Sanofi is profitable and controls its share count, but its sales growth (2.7%/year) and especially its free cash flow per share (-6.2%/year, declining) fall below my thresholds, with compressing margins.

Why is Sanofi's free cash flow per share declining while Dupixent is booming?

It is the classic pharma patent cliff: Sanofi's older drugs lose protection and face generic competition, eroding sales, while a single product (Dupixent) carries most of the growth and diversification R&D (lunsekimig, amlitelimab) weighs on cash available today.

Isn't a 16.5x P/FCF cheap for Sanofi?

It is cheap versus sector peers (34th percentile, below the median). But versus its own five-year history, that same level sits at the 79th percentile: Sanofi has rarely paid this much for its own cash.

What will Dupixent's 2031 patent expiry change?

Dupixent's main patent expires in 2031, giving Sanofi a window to build what comes next: a new quarterly-dosing formulation entering trials in the second half of 2026, an extension into high-dose asthma, and a diversified pipeline (lunsekimig, amlitelimab) that just delivered positive phase II results.

Should you buy Sanofi stock now?

My quality screen is mixed (5 of 10 criteria), and my price model shows a severe 52.9% overvaluation that leaves no margin of safety at the current price. This is not personalized investment advice, do your own research before any decision.

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).